FMP
Kymera Therapeutics, Inc.
KYMR
NASDAQ
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
34.37 USD
0.92 (2.68%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
159.74M
305.44M
437.86M
582.02M
714.73M
1.05B
1.56B
2.3B
3.39B
5B
Revenue %
-
91.21
43.35
32.93
22.8
47.57
47.57
47.57
47.57
Ebitda
1.51M
106.37M
143.57M
221.51M
233.41M
293.81M
433.57M
639.83M
944.22M
1.39B
Ebitda %
0.95
34.82
32.79
38.06
32.66
27.86
27.86
27.86
27.86
Ebit
-8.72M
87.53M
120.19M
197.15M
209.3M
240.06M
354.27M
522.8M
771.5M
1.14B
Ebit %
-5.46
28.66
27.45
33.87
29.28
22.76
22.76
22.76
22.76
Depreciation
10.24M
18.84M
23.39M
24.36M
24.11M
53.74M
79.31M
117.04M
172.71M
254.88M
Depreciation %
6.41
6.17
5.34
4.19
3.37
5.1
5.1
5.1
5.1
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
